

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application.

Listing of Claims:

1-20. (Canceled)

21. (Currently amended) ~~The therapeutic agent of claim 18, wherein the polypeptide comprises~~ A therapeutic agent comprising

(a) a first domain that binds a first protein, the first protein having at least seven consecutive glutamine residues;

(b) a second domain that binds a second protein, the second protein having at least seven consecutive glutamine residues; and

(c) a third domain that (i) consists of a polypeptide comprising an alpha-helical region or a beta-sheet and (ii) separates the first domain from the second domain, wherein the therapeutic agent inhibits an abnormal or undesirable interaction between the first protein and the second protein and wherein the first domain and/or the second domain comprises a polypeptide comprising at least 80% glutamine residues.

22. (Previously presented) The therapeutic agent of claim 21, wherein the polypeptide comprises at least 85%, 90%, 95%, or 98% glutamine residues.

23. (Currently amended) ~~The therapeutic agent of claim 1,~~ A therapeutic agent comprising

(a) a first domain that binds a first protein, the first protein having at least seven consecutive glutamine residues;

(b) a second domain that binds a second protein, the second protein having at least seven consecutive glutamine residues; and

(c) a third domain that (i) consists of a polypeptide comprising an alpha-helical region or a beta-sheet and (ii) separates the first domain from the second domain, wherein the therapeutic

agent inhibits an abnormal or undesirable interaction between the first protein and the second protein and wherein the first domain and/or the second domain comprises a polypeptide comprising the first 17 amino acid residues of the Huntingtin protein fused to 25 consecutive glutamine residues and, optionally, a sufficient number of hydrophilic amino acid residues to increase the solubility of the therapeutic agent, the hydrophilic amino acid residues including at least one aspartic acid residue or glutamic acid residue.

24. (Currently amended) ~~The therapeutic agent of claim 1,~~ A therapeutic agent comprising  
(a) a first domain that binds a first protein, the first protein having at least seven  
consecutive glutamine residues;

(b) a second domain that binds a second protein, the second protein having at least seven  
consecutive glutamine residues; and

(c) a third domain that (i) consists of a polypeptide comprising an alpha-helical region or  
a beta-sheet and (ii) separates the first domain from the second domain, wherein the therapeutic  
agent inhibits an abnormal or undesirable interaction between the first protein and the second  
protein and wherein the first and second domains are identical.

25. (Currently amended) The therapeutic agent of ~~claim 19~~ claim 24, wherein ~~the first~~  
~~and second domains are identical~~ the first domain and/or the second domain comprises a  
polypeptide comprising 3, 7, 10, 20, 30, 37, 38, 39, 40, 50, 75, 100, 150, 200, 250, or 300  
consecutive glutamine residues and, optionally, a sufficient number of hydrophilic amino acid  
residues to increase the solubility of the therapeutic agent, the hydrophilic amino acid residues  
including at least one aspartic acid residue or glutamic acid residue.

26. (Previously presented) The therapeutic agent of claim 21, wherein the first and second domains are identical.

27. (Previously presented) The therapeutic agent of claim 23, wherein the first and second domains are identical.

28-30. (Canceled)

31. (Currently amended) ~~The therapeutic agent of claim 30,~~ A therapeutic agent comprising

(a) a first domain that binds a first protein, the first protein having at least seven consecutive glutamine residues;

(b) a second domain that binds a second protein, the second protein having at least seven consecutive glutamine residues; and

(c) a third domain, wherein the third domain consists of a polypeptide comprising the sequence of a TATA-binding protein or a fragment thereof and, optionally, a sufficient number of hydrophilic amino acid residues to increase the solubility of the therapeutic agent, the hydrophilic amino acid residues including at least one aspartic acid residue or glutamic acid residue, wherein the TATA-binding protein consists of the sequence of SEQ ID NO:12.

32. (Currently amended) ~~The therapeutic agent of claim 30,~~ A therapeutic agent comprising

(a) a first domain that binds a first protein, the first protein having at least seven consecutive glutamine residues;

(b) a second domain that binds a second protein, the second protein having at least seven consecutive glutamine residues; and

(c) a third domain, wherein the third domain consists of a polypeptide comprising the sequence of a TATA-binding protein or a fragment thereof and, optionally, a sufficient number of hydrophilic amino acid residues to increase the solubility of the therapeutic agent, the hydrophilic amino acid residues including at least one aspartic acid residue or glutamic acid residue, wherein the fragment of the TATA-binding protein consists of the alpha-helical region

H1 (SEQ ID NO:2), the alpha-helical region H2 (SEQ ID NO:3), the alpha-helical region H3 (SEQ ID NO:4), or the alpha-helical region H4 (SEQ ID NO:5), a fusion of H1/H2 (SEQ ID NO:6), a fusion of H2/H3 (SEQ ID NO:7), or a fusion of H3/H4 (SEQ ID NO:8).

33. (Currently amended) ~~The therapeutic agent of claim 30,~~ A therapeutic agent comprising

(a) a first domain that binds a first protein, the first protein having at least seven consecutive glutamine residues;

(b) a second domain that binds a second protein, the second protein having at least seven consecutive glutamine residues; and

(c) a third domain, wherein the third domain consists of a polypeptide comprising the sequence of a TATA-binding protein or a fragment thereof and, optionally, a sufficient number of hydrophilic amino acid residues to increase the solubility of the therapeutic agent, the hydrophilic amino acid residues including at least one aspartic acid residue or glutamic acid residue, wherein the third domain consists of a polypeptide comprising SEQ ID NO:11.

34.-35. (Canceled)

36. (Currently amended) ~~The therapeutic agent of claim 35,~~ A therapeutic agent comprising

(a) a first domain that binds a first protein, the first protein having at least seven consecutive glutamine residues;

(b) a second domain that binds a second protein, the second protein having at least seven consecutive glutamine residues; and

(c) a third domain that (i) consists of a polypeptide comprising an alpha-helical region or a beta-sheet and (ii) separates the first domain from the second domain, wherein the therapeutic agent inhibits an abnormal or undesirable interaction between the first protein and the second protein; wherein the first and/or second protein comprises 7, 10, 15, 20, 25, 30, 35, 36, 37, 38,

39, or 40 consecutive glutamine residues; and wherein the first and/or second protein is Huntingtin.

37. (Currently amended) ~~The therapeutic agent of claim 35,~~ A therapeutic agent comprising  
(a) a first domain that binds a first protein, the first protein having at least seven  
consecutive glutamine residues;

(b) a second domain that binds a second protein, the second protein having at least seven  
consecutive glutamine residues; and

(c) a third domain that (i) consists of a polypeptide comprising an alpha-helical region or  
a beta-sheet and (ii) separates the first domain from the second domain, wherein the therapeutic  
agent inhibits an abnormal or undesirable interaction between the first protein and the second  
protein; wherein the first and/or second protein comprises 7, 10, 15, 20, 25, 30, 35, 36, 37, 38,  
39, or 40 consecutive glutamine residues; and wherein the first and/or second protein is an  
amyloid-associated protein.

38. (Currently amended) ~~The therapeutic agent of claim 35,~~ A therapeutic agent comprising  
(a) a first domain that binds a first protein, the first protein having at least seven  
consecutive glutamine residues;

(b) a second domain that binds a second protein, the second protein having at least seven  
consecutive glutamine residues; and

(c) a third domain that (i) consists of a polypeptide comprising an alpha-helical region or  
a beta-sheet and (ii) separates the first domain from the second domain, wherein the therapeutic  
agent inhibits an abnormal or undesirable interaction between the first protein and the second  
protein; wherein the first and/or second protein comprises 7, 10, 15, 20, 25, 30, 35, 36, 37, 38,  
39, or 40 consecutive glutamine residues; and wherein the first and/or second protein is a  
transcription factor.

39. (Canceled)

40. (Currently amended) ~~The therapeutic agent of claim 1,~~ A therapeutic agent comprising  
(a) a first domain that binds a first protein, the first protein having at least seven  
consecutive glutamine residues;  
(b) a second domain that binds a second protein, the second protein having at least seven  
consecutive glutamine residues; and  
(c) a third domain that (i) consists of a polypeptide comprising an alpha-helical region or  
a beta-sheet and (ii) separates the first domain from the second domain, wherein the therapeutic  
agent inhibits an abnormal or undesirable interaction between the first protein and the second  
protein and wherein the interaction is aggregation.

41. (Previously presented) The therapeutic agent of claim 40, wherein the aggregation between a population of proteins consisting of the first protein and a population of proteins consisting of the second protein is inhibited by at least 25%.

42. (Previously presented) The therapeutic agent of claim 40, wherein the aggregation is inhibited by at least 30%, 40%, 50%, 60%, 70%, 80%, or 90%.

43. (Currently amended) ~~The therapeutic agent of claim 1,~~ A therapeutic agent comprising  
(a) a first domain that binds a first protein, the first protein having at least seven  
consecutive glutamine residues;  
(b) a second domain that binds a second protein, the second protein having at least seven  
consecutive glutamine residues; and  
(c) a third domain that (i) consists of a polypeptide comprising an alpha-helical region or  
a beta-sheet and (ii) separates the first domain from the second domain, wherein the therapeutic  
agent inhibits an abnormal or undesirable interaction between the first protein and the second  
protein and wherein the interaction is dimerization.

44.-45. (Canceled)

46. (Currently amended) ~~The composition of claim 44,~~ A pharmaceutically acceptable composition comprising a therapeutic agent, wherein the therapeutic agent comprises

(a) a first domain that binds a first protein, the first protein having at least seven consecutive glutamine residues;

(b) a second domain that binds a second protein, the second protein having at least seven consecutive glutamine residues; and

(c) a third domain that separates the first domain from the second domain, wherein the therapeutic agent inhibits interaction between the first protein and the second protein and  
wherein the first and/or second protein is Huntingtin; the first and/or second protein is an amyloid-associated protein; or the first and/or second protein is a transcription factor.